The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -143,558 |
| Payment of operating costs through promissory note | 77,800 |
| Interest earned on cash and investments held in trust account | 109,355 |
| Prepaid expenses | -27,580 |
| Due from sponsor | 566,269 |
| Accounts payable | 4,592 |
| Accrued expenses | 5,843 |
| Net cash used in operating activities | -703,367 |
| Investment of cash into trust account | 500,000,000 |
| Net cash used in investing activities | -500,000,000 |
| Proceeds from sale of units, net of underwriting discounts paid | 490,000,000 |
| Proceeds from sale of private placement units | 12,000,000 |
| Repayment of promissory note - related party | 533,781 |
| Payment of offering costs | 464,800 |
| Net cash provided by financing activities | 501,001,419 |
| Net change in cash | 298,052 |
| Cash and cash equivalents at beginning of period | 17,035 |
| Cash and cash equivalents at end of period | 315,087 |
Drugs Made In America Acquisition II Corp. (DMII)
Drugs Made In America Acquisition II Corp. (DMII)